Vera Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Vera Therapeutics submitted a Biologics License Application for its lead candidate, atacicept, for IgAN after positive Phase 3 results, receiving FDA Priority Review.
NASDAQ
Vera Therapeutics advances atacicept for IgAN, anticipates Phase 3 results in Q2 2025, and expands its pipeline with VT-109 acquisition.
NASDAQ
Vera Therapeutics details its common stock structure, voting rights, and anti-takeover provisions in a recent SEC filing.